

**ELENCO DEI PRINCIPALI RIFERIMENTI BIBLIOGRAFICI
RELATIVI AL SEMINARIO DI MARCO DE AMICI DEL 09.04.2026**

- 1) Of War and Peace, and Chemistry I. S. Martinez, G. Povoden, *ACS Chem. Health Saf.* **2025**, 32, 223-227, doi.org/10.1021/acs.chas.5c00044
- 2) Medicinal Chemistry: A Key Driver in Achieving the Global Sustainable Development Goals. B. Martinengo et al., *J. Med. Chem.* **2025**, 68, 6916-6931, doi.org/10.1021/acs.jmedchem.4c03016
- 3) Benign-by-Design SAHA Analogues for Human and Animal Vector-Borne Parasitic Diseases. M. Rossi et al., *ACS Med. Chem. Lett.* **2024**, 15, 1506-1515, doi.org/10.1021/acsmedchemlett.4c00242
- 4) Harnessing the 12 Green Chemistry Principles for Sustainable Antiparasitic Drugs: Toward the One Health Approach B. Martinengo et al., *ACS Infect. Dis.* **2024**, 10, 1856-1870, doi.org/10.1021/acsinfecdis.4c00172
- 5) A New Formulation of Praziquantel to Achieve Schistosomiasis Elimination. G. J. Yang, X. N. Zhou, *Lancet Infect. Dis.* **2023**, 23, 774-776, doi.org/10.1016/S1473-3099(23)00059-2
- 6) Sudan: from a Forgotten War to an Abandoned Healthcare System. A. Elamin, S. Abdullah et al., *BMJ Glob. Health* **2024**, 9, e016406, doi.org/10.1136/bmjgh-2024-016406
- 7) Sustainability in Drug Discovery. E. Wynendaele, C. Furman et al., *Med. Drug Disc.* **2021**, 12, 100107, doi.org/10.1016/j.medidd.2021.100107
- 8) Sustainability of Drug Discovery, Development and Use as Embedded in European Pharmaceutical Policies. B. De Spiegeleer, E. Wynendaele, *Curr. Opin. Green Sustain. Chem.* **2025**, 53, 101028, doi.org/10.1016/j.cogsc.2025.101028
- 9) Green Chemistry Approaches in Pharmaceutical Synthesis: Sustainable Methods for Drug Development. Stefanache et al., *AppliedChem* **2025**, 5, 13, doi.org/10.3390/appliedchem5020013
- 10) Lenacapavir: a Giant Step forward in HIV Prevention-but a Missed Opportunity for Achieving Equity and Access. G. Yamey, S. Machingaidze, *BMJ* **2024**, 387, q2254, doi.org/10.1136/bmj.q2254
- 11) Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis. E. Canales et al., *J. Med. Chem.* **2025**, 68, 21072-21094, doi.org/10.1021/acs.jmedchem.5c01625

- 12) The United Nations' Ambitious Roadmap against Tuberculosis: Opportunities, Challenges and the Imperative of Equity. B. H. Gulumbe et al., *FUTURE SCIENCE OA* **2024**, *10*, 2418787. doi.org/10.1080/20565623.2024.2418787
- 13) Report: Investing in Innovation and Equitable Access to End the Tuberculosis Epidemic (A Global Partnership and Collaborative Initiative, October 2024). [Investing in innovation and equitable access to end the tuberculosis epidemic - Results UK](#)
- 14) Behind-the-Scenes Investment for Equity in Global Health Research. J. E. Haberer, Y. Boum II, *N. Engl. J. Med.* **2023**, *388*, 387-390, 10.1056/NEJMp2213809
- 15) Challenges and Applications of Artificial Intelligence in Infectious Diseases and Antimicrobial Resistance. A. Cesaro et al. *npj Antimicrob. Resist.* **2025**, *3*, 2, <https://doi.org/10.1038/s44259-024-00068-x>
- 16) Artificial Intelligence for Drug Discovery: Are We There Yet? C. Hesselgren, T. I. Oprea, *Annu. Rev. Pharmacol. Toxicol.* **2024**, *64*, 527-550, doi.org/10.1146/annurev-pharmtox-040323-040828
- 17) Has AI Reshaped Drug Discovery, or Is There Still a Long Way to Go? K. S. Harini, D. Ezhilarasan, *Drug Dev. Res.* **2026**, *87*, e70257, doi.org/10.1002/ddr.70257
- 18) Intelligenza Artificiale e Salute: come L'IA sta rivoluzionando la ricerca farmaceutica, la medicina di precisione e il futuro della salute globale. *Dossier AIFA* (marzo **2026**), https://www.aifa.gov.it/documents/20142/3346516/Dossier_stamp_aIFA_e_Salute.pdf